Is prolonged immobilization a risk factor for symptomatic venous thromboembolism in elderly bedridden patients?

Summary

Prolonged immobilization and advanced age are considered to be important risk factors for venous thromboembolism (VTE). Nevertheless, the need for VTE prophylaxis in long-term bedridden patients is not known. To assess whether very prolonged immobilization (i.e. over three months) carries an increased risk for clinically apparent VTE, we performed a historical-cohort study of nursing home residents during a ten-year period. Data concerning patient’s mobility and incidence of overt deep vein thrombosis or pulmonary embolism were registered. The mean resident age was 85 ± 8.4 years. Eighteen mobile and eight immobile patients were diagnosed with clinically significant thromboembolic events, during 1137 and 573 patient-years of follow up, respectively. The incidence of venous thromboembolic events was similar in both chronically immobilized and mobile patient groups, 13.9 and 15.8 per thousand patient years, respectively (p = 0.77). The rate ratio for having a VTE event in the immobilized patient group as compared with the mobile group was 0.88 (95% Confidence Interval (CI) 0.33 to 2.13). When taking into account baseline characteristics, risk factors and death rates by various causes, no differences were found between the two groups. In conclusion, chronically immobile bedridden patients are no more prone to clinically overt venous thromboembolic events than institutionalized mobile patients. Until further studies are performed concerning the impact of very prolonged immobilization on the risk of VTE, there is no evidence to support primary prevention after the first three months of immobilization. Evidence for efficacy or cost effectiveness beyond this early period is not available.

Keywords

Venous thromboembolism - prolonged immobilization - bedridden - prevention - prophylaxis

• References

• 1 Hull RD, Pineo GF. Prophylaxis of deep vein thrombosis and pulmonary embolism. Current recommendations. Med Clin North Am 1998; 82: 477-93.
• 2 Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353: 1167-73.
• 3 Nordstrom M, Lindblad B, Bergqvist D. et al. A prospective study of the incidence of deep vein thrombosis within a defined urban population. J Intern Med 1992; 232: 155-60.
• 4 Oger E. et al. Incidence of venous thromboembolism: A community-based study in western France. Thromb Haemost 2000; 83: 657-60.
• 5 Silverstein MD, Heit JA, Mohr DN. et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism. Arch Intern Med 1998; 158: 585-93.
• 6 Geerts WH, Heit JA, Clagett GP. et al. Prevention of venous thromboembolism. Chest 2001; 119: s132-s75.
• 7 Virchow R. Ein Vortag über die Thrombose von Jahre. Virchow R. Gesammelte Abhandlungen zur wissenschaftlichen Medizin. Frankfurt: Meidinger; 1845: 478-86.
• 8 Mammen EF. Pathogenesis of venous thrombosis. Chest 1992; 102: 640-4.
• 9 Flordal PA, Bergqvist D, Burmark US. et al. Risk factors for major thromboembolism and bleeding tendency after elective general surgical operations. Eur J Surg 1996; 162: 783-89.
• 10 Anderson FA, Brownwell HWheeler. et al. A population based perspective of the hospital incidence and case fatality rates of deep vein thrombosis and pulmonary embolism. Arch Intern Med 1991; 151: 933-8.
• 11 Cogo A, Bernardi E, Prandoni P. et al. Acquired risk factors for deep vein thrombosis in symptomatic outpatients. Arch Intern Med 1994; 154: 164-8.
• 12 Samama MM. et al. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients. Arch Intern Med 2000; 160: 3415-20.
• 13 Heit JA, Silverstein MD, Mohr DN. et al. Risk factors for deep vein thrombosis and pulmonary embolism. Arch Intern Med 2000; 160: 809-15.
• 14 Oczkowski WJ, Ginsberg JS, Shin A. et al. Venous thromboembolism in patients undergoing rehabilitation for stroke. Arch Phys Med Rehabil 1992; 73: 712-6.
• 15 Angelli G, Mancini GB, Biagini D. The rationale for long term prophylaxis of venous thromboembolism. Orthopedics 2000; 23: s643-6.
• 16 Bergqvist D. Prolonged prophylaxis against postoperative venous thromboembolism. Haemostasis 1996; 26: 379-87.
• 17 Planes A, Vochelle N, Darmon JY. et al. Risk for deep venous thrombosis after hospital discharge in patient having undergone total hip replacement: double-blind randomized comparison of enoxaparin versus placebo. Lancet 1996; 348: 224-8.
• 18 Lederle FA. Heparin prophylaxis for medical patients?. Ann Intern Med 1998; 128: 768-70.
• 19 Gallus AS, Nurmohammed M, Kearon C. et al. Thromboprophylaxis in non-surgical patients: Who, when and how. Haemostasis 1988; 28: 71-82.
• 20 Anderson LC, Cutter NC. Immobility. Hazzard WR, Blass JP, Ettinger WH, Halter JB, Ouslander JG. Principles of geriatric medicine and gerontology. 4th Ed.. New York: McGraw-Hill; 1999: 1565-75.
• 21 Gallus AS. Preventing venous thromboembolism in general medical inpatients and after an ischaemic stroke. Haemostasis 2000; 30: 67-71.
• 22 Trivalle C. Long-term use of low molecular weight heparin for venous thromboembolism prophylaxis in French geriatric settings. J Gerontol 2001; 56A: M463-M464.
• 23 Hitosugi M, Niwa M, Takatsu A. Rheologic changes in venous blood during prolonged sitting. Thromb Res 2000; 100: 409-12.
• 24 Kaperonis AA, Michelsen CB, Askanazi J. et al. Effects of total hip replacement on blood rheology and red cell metabolism. J Trauma 1988; 28: 453-7.
• 25 Ernest E, Schmidt-Pauly E, Muhlig P. et al. Blood viscosity in patients with bone fractures and long term bed-rest. Br J Surg 1987; 74: 301-2.
• 26 Petaja J, Myllynen P, Rokkanen P. et al. Fibrinolysis and spinal injury. Acta Chir Scand 1989; 155: 241-6.
• 27 Keber D. The increase of leg fibrinolytic potential after reduction of hydrostatic stimulus. Thromb Haemost 1983; 50: 731-4.
• 28 Rawles JM, Warlow C, Ogston D. Fibrinolytic capacity of arm and leg veins after femoral shaft fracture and acute myocardial infarction. Br Med J 1975; 02: 61-2.
• 29 Myllynen P, Kammonen M, Rokkanen P. et al. The blood F VIII:Ag/F VIII:C ratio as an early indicator of deep venous thrombosis during post-traumatic immobilization. J Traum 1987; 27: 287-90.
• 30 Benoist M, Barrellier MT, Gautier P. et al. Venous thromboembolic disease in a geriatric environment. Importance of detection and treatment. J Mal Vasc 1994; 19: 289-93.
• 31 Heit JA, O’Fallon M, Petterson TM. et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism. Arch Intern Med 2002; 162: 1245-8.
• 32 Jackson SA. The epidemiology of aging. Hazzard WR, Blass JP, Ettinger WH, Halter JB, Ouslander JG. Principles of geriatric medicine and gerontology. 4th Ed.. New York: McGraw-Hill; 1999: 203-25.
• 33 Hirsh J. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119: 64-94.
• 34 Isaacs C, Paltiel O, Beaudet M. et al. Ageassociated risks of prophylactic anticoagulation in the setting of hip fracture. Am J Med 1994; 96: 487-91.